Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.41 |
| ▸ | POLRMT | O00411 | 1/20 | 0.32 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26637240 | 0.90 | TMPRSS2 (0.43) | TMPRSS2POLRMTRNASEL | |
| SCHEMBL24917155 | 0.90 | TMPRSS2 (0.45) | TMPRSS2POLRMTRNASEL | |
| SCHEMBL31684109 | 0.90 | TMPRSS2 (0.40) | TMPRSS2POLRMT | |
| SCHEMBL26651233 | 0.90 | POLRMT (0.33) | POLRMTBTN3A1RNASEL | |
| SCHEMBL26637298 | 0.90 | TMPRSS2 (0.39) | TMPRSS2POLRMT | |
| SCHEMBL26637301 | 0.90 | TMPRSS2 (0.39) | TMPRSS2POLRMT | |
| SCHEMBL31684063 | 0.86 | TMPRSS2 (0.43) | TMPRSS2POLRMTRNASEL | |
| SCHEMBL30939781 | 0.86 | TMPRSS2 (0.43) | TMPRSS2POLRMTRNASEL | |
| SCHEMBL31684188 | 0.86 | TMPRSS2 (0.43) | TMPRSS2POLRMTRNASEL | |
| SCHEMBL30921699 | 0.85 | TMPRSS2 (0.39) | TMPRSS2POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | MIRACURE BIOTECHNOLOGY LTD (CN) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338409-A1 | NUCLEOSIDE DRUGS FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION AND THEIR USES | PNP, MTAP, TYMP | TMPRSS2 149/4885POLRMT 210/4885BTN3A1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.